The possible association between pulmonary tuberculosis (TB) and lung cancer development has been studied for several decades. However, the association between epidermal growth factor receptor (EGFR) mutation status and pulmonary TB in patients with adenocarcinoma of the lungs is unknown.
L
ung cancer is the leading cause of cancer death throughout the world. Approximately 12.4% of all newly diagnosed cancer cases are lung cancers, and lung cancer accounts for 29% of all cancer deaths. 1 Tuberculosis (TB) is one of the major causes of death among infectious diseases and remains a global public health threat. The majority of TB infections are pulmonary TB. It has been proposed that pulmonary TB infection may exist as a chronic inflammatory process that is associated with an increased risk of lung cancer. This is because the pulmonary inflammation and fibrosis may induce genetic damage, which leads to carcinogenesis of the pulmonary parenchymal tissue. [2] [3] [4] [5] It has been reported that some cases of lung cancer, usually adenocarcinoma in type, that arise from pulmonary scars were the result of healed pulmonary TB infection. 6 -8 The frequency of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer ranges from 5 to 30% and depends on the population studied. 9 -12 Patients with lung cancer whose tumors exhibited EGFR-activating mutations had approximately 75% response rate when treated with EGFR-tyrosine kinase inhibitors (TKIs), whereas those patients without EGFR-activating mutations responded to EGFR-TKI poorly. 9, 13, 14 In addition, patients with lung cancer with tumor EGFR-activating mutations survived longer than those without. 15, 16 The incidence of tumor EGFR mutations was found to be higher in East Asian countries, such as Taiwan, as was the prevalence of pulmonary TB infection. [17] [18] [19] However, there was no report on tumor EGFR mutation status in patients with lung cancer with or without pulmonary TB, nor was EGFR mutation status correlated with pulmonary TB. The clinical characteristics of patients with lung cancer who have pulmonary TB and an EGFR mutation have also not been discussed. We therefore conducted this retrospective study to determine whether there is a difference in the clinical manifestations and patient survival between tumor EGFR mutation status and pulmonary TB.
PATIENTS AND METHODS
We retrospectively reviewed the chart records of our patients with pulmonary adenocarcinoma who had received diagnosis, staging, and treatment in our hospital from 1999 to 2011. Histories of having been diagnosed with pulmonary TB and chest computed tomography (CT) images compatible with previous tuberculous infection were also recorded. A clinical history of pulmonary TB is defined as a consistent chest image pattern and having received anti-TB treatment previously. This review was approved by the institutional review board of our hospital (VGHIRB 2011-04-0151A). Lung cancer staging was evaluated according to the sixth edition of the tumor node metastasis staging system for non-small cell lung cancer. Patients with a histological diagnosis of adenocarcinoma of the lungs were classified as patients with a history of pulmonary TB disease or not, patients with chest CT images revealing old pulmonary TB lesion(s) or not, and patients with chest CT images suggestive of scar cancer or not.
The existence and location of pulmonary TB lesions were determined on the basis of chest CT scan findings. All images were analyzed by three independent reviewers. Chest CT scans were evaluated for fibrotic change, fibronodular lesions, pleural thickening, calcified nodules, scars, the location of the primary tumor, and TB lesions in the same or Performance status (ECOG)  0  3  11  56  68  1  9  47  126  176  2  5  14  17  31  Lung cancer  staging  I  0  3  2 0  2 3  II  0  1  4  5  IIIa  2  6  12  19  IIIb  0  4  20  24  IV  15  58  143  204  Scar cancer  4  14  0 a Ipsilateral, the main lesion of PTB was located in the same hemithorax as that of lung cancer; contralateral, the main lesion of PTB lay in the hemithorax contralateral to that of cancer; and same lobe, PTB affected the same lobe as that of lung cancer.
b With tumor EGFR mutation other than an exon 19 mutation and L858R point mutation.
Group A, patients with a history of pulmonary TB disease; group B, patients with old pulmonary TB lesions on chest CT scan; group C, patients without history of pulmonary TB disease and old pulmonary TB lesions on chest CT scan; ECOG, Eastern Cooperative Oncology Group; TB, tuberculosis; EGFR, epidermal growth factor receptor; CT, computed tomography; PTB, pulmonary tuberculosis. c Two patients with R836P also have L858R mutation, and they were not included in 18 patients with exon 21 mutation other than L858R point mutation.
EGFR, epidermal growth factor receptor.
different lobe of the primary lesion of lung cancer. Lesions with calcified granulomas, fibronodular lesions, or pleural thickening in favor of previous granulomatous inflammation were regarded as old TB lesions. 20 Scar cancer included lung cancer arising from old pulmonary TB lesions that had thus merged with fibrotic scars or granuloma lesions. 21 After reviewing the chest CT scans, the three reviewers reached a final diagnosis by consensus. EGFR mutation analysis was performed with nucleotide sequence analysis. 22 The VarientSEQr Resequencing Primer Set was selected for mutational analysis of the tyrosine kinase domain and exons 18 to 21 of the EGFR gene. Genomic DNA was extracted from paraffin blocks, exons 18 to 21 were amplified, and uncloned polymerase chain reaction fragments were sequenced and analyzed in both sense and antisense directions for the presence of heterozygous mutations. Normal control DNA provided by the ABI Company was used for wild-type control. All the sequence variations were confirmed by multiple, independent polymerase chain reaction amplifications and repeated sequencing reactions. Tumor EGFR mutations were defined as those with exons 18 to 21 mutations. The associations between EGFR mutation and past pulmonary TB and old TB lesions were evaluated using Pearson's 2 test and multivariate logistic regression analysis.
Survival was measured from the date of initiation of treatment to the date of death or last follow-up. For statistical analysis, the Kaplan-Meier method with a log-rank test and Cox proportional hazard model were used for survival analysis.
RESULTS
From June 1999 to January 2011, 275 patients with adenocarcinoma of the lung had tumor EGFR mutation status data available for analysis. Of these patients, 131 (47.6%) were men and 144 (52.4%) were women (Table 1) . Among all patients, 17 (6.2%) had a history of pulmonary TB, 72 (26.2%) had old TB lesions on the chest CT scan, and 14 (5.1%) had scar cancer. Of all patients, 191 (69.5%) had an EGFR mutation (118 exon 19 deletions, 59 exon 21 L858R point mutation, including 11 patients with both exon 19 deletions and exon 21 L858R, 8 exon 18 mutations, and 10 exon 20 mutations; Tables 1 and 2) , and 84 patients (30.5%) were EGFR wild type.
Patients with old TB lesions found on chest CT scans had a higher incidence of EGFR mutations (58 patients, 80.6%) than those without (133 patients, 65.5%; p ϭ 0.018, Table 3 ). All patients with scar cancer had an EGFR mutation, but those with lung cancer other than scar cancer had a lower proportion of EGFR mutations (100% versus 67.8%, p ϭ 0.007). Exon 19 deletions occurred more frequently in patients with old TB lesions found on chest CT scans than in patients without (68.1% versus 34%; p Ͻ 0.001). Patients with scar cancer had a higher incidence of exon 19 deletions (13 of 14) than the remaining patients without scar cancer (92.9% versus 40.2%; p Ͻ 0.001). A lower proportion of patients with old TB lesions found on chest CT scans had L858R mutations than patients without (8.3% versus 26.1%, p ϭ 0.007). Thus, old TB lesions and scar cancer had a statistically significant association with EGFR mutation, especially exon 19 deletions. The odds ratios for exon 19 deletions were 19.31 (95% CI: 2.49 -149.87) among patients with scar cancer, 4.14 (95% CI: 2.33-7.35) among patients with old TB lesions on chest CT scans, and 1.99 (95% CI: 0.73-5.38) among patients with a history of pulmonary TB. Multivariate analysis for prediction of tumor EGFR mutation was performed. After adjusting for possible confounders, the multivariate analysis revealed that the odds ratio for tumor EGFR mutation among patients with old TB lesions was 1.83 (95% CI: 0.92-3.62; p ϭ 0.038; Table 4 ). Among patients with old TB lesions found on chest CT scans, there was a higher proportion of patients with an EGFR mutation (p ϭ 0.039), especially exon 19 deletions (p Ͻ 0.001; Table 5 ), and especially in patients who had lung cancer and old TB lesions in the same lobe or same side of the lung, than those who had lung cancer and old TB lesions in the opposite side of the lung. Most of the patients with lung cancer and old TB lesions in the same lobe of the lung did not have L858R mutations (p ϭ 0.022): only 4 of 40 patients (10%) who had lung cancer and old TB lesions in the same lobe had L858R mutations.
Survival analysis showed that patients with adenocarcinoma who had old TB lesions (n ϭ 72) survived for a c Ipsilateral, the main lesion of PTB was located in the same hemithorax as that of lung cancer; contralateral, the main lesion of PTB lay in the hemithorax contralateral to that of cancer; and same lobe, PTB affected the same lobe as that of lung cancer.
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shorter period than those who did not (n ϭ 202; 1-year survival rate 77% versus 85.8%; p ϭ 0.015; Figure 1 ; Table  6 ) in the entire study population based on the unadjusted analysis. Similar results were obtained from Cox regression analysis adjusted for covariates, including EGFR mutations and tumor stage (Table 7) . Among all patients' characteristics, having old TB lesions coincide with shorter overall survival than its contrary, independent of having EGFR mutation or not. On the other hand, overall survival was not influenced by the patient's gender, age, smoking history, tumor stage, performance status, and EGFR-TKIs treatment. When the survival time of patients with exon 19 deletions (n ϭ 117) was compared with that of EGFR wild-type patients (n ϭ 84), the former had survived longer than the latter (1-year survival rate 88.6% versus 76.3%; p ϭ 0.015; Figure 2 ; Table 6 ). When survival was compared between patients who had EGFR mutations (either exon 19 deletions or L858R mutation) and those who were EGFR wild type, those who had EGFR mutations (n ϭ 121) had survived longer than those who had EGFR wild type (n ϭ 84; 1-year survival rate 87% versus 76.3%; p ϭ 0.025, median survival had not been reached; Table 6 ).
In patients with tumor EGFR wild type, those who had old TB lesions (n ϭ 14) survived for a shorter period than those did not (n ϭ 70; 1-year survival rate 35.4% versus 82.1%; p ϭ 0.009; Figure 3 ; Table 6 ). Among patients with EGFR mutations, those who had old TB lesions (n ϭ 58) survived for a shorter period than those who did not (n ϭ 133; 1-year survival rate 84.6% versus 86.7%; p ϭ 0.035; Figure  4 ; Table 6 ). However, with or without old TB lesions did not affect overall survival among patients with exon 19 deletions (p ϭ 0.271; Table 6 ). In patients with old TB lesions, those who had EGFR mutations or exon 19 mutations survived longer than those who did not have mutations. (p ϭ 0.014 and 0.001, respectively; Table 6 ).
DISCUSSION
This is the first study to investigate the association between tumor EGFR mutations and pulmonary TB. The coexistence of pulmonary TB and lung cancer has been noted for many decades and poses considerable challenges for the diagnosis and treatment. Many studies have suggested that pulmonary TB plays an important role in the formation of follow-on lung cancer and that pulmonary TB is associated with an increased risk of lung cancer. The pathogenic linkage between pulmonary TB and lung cancer is still unclear. A chronic inflammatory process because of latent TB infection may serve as a cause of lung carcinogenesis and results in remodeling of lung tissue, activation of an atypical differentiation pathway, and finally malignant transformation. 23 Ar-FIGURE 2. Survival curve of patients with EGFR exon 19 deletions or EGFR wild type. When the survival time of patients with exon 19 deletions (n ϭ 117) was compared with that of EGFR wild-type patients (n ϭ 84), those who had exon 19 deletions survived longer than those with EGFR wild type (1-year survival rate 88.6% versus 76.3%, p ϭ 0.015). EGFR, epidermal growth factor receptor. dies 24 suggested that lung scarring occurred as a result of spontaneous healing after repeated pulmonary TB infections and produced a favorable environment for tumor growth. Nalbandian et al. 23 postulated that chronic TB infection may lead to DNA-damaging reactive oxygen and nitrogen species and that the MTB-infected macrophages produce a most potent member of the epidermal growth factor family, epiregulin, which may play an important role as a paracrine growth factor during the initial steps of carcinogenesis. Edwards and Carlile 25 suggested that a proportion of lung cancers arise at the edge of preexisting pulmonary scars and that the lung parenchymal scarring could promote atypical epithelial cell proliferation and metaplasia in the terminal airspace. Our findings of a significant association between EGFR mutation and pulmonary TB further support these hypotheses: patients with adenocarcinoma, who had scar cancer and old TB lesions, had a higher probability of having EGFR mutations, especially exon 19 deletions. Our data also showed that patients with scar cancer had the highest odds ratios (19.31) for exon 19 deletions, followed by those with old TB lesions (odds ratio of 4.14) and a history of pulmonary TB (odds ratio of 1.99). The scarring process of old TB lesions may play an important role in the formation of lung cancer. A previous study also showed that individuals with a clinical history of TB had a fivefold higher risk of lung cancer than a control group. 26 Because patients with old TB lesions on chest CT scans had a lower probability of having a L858R point mutation (p ϭ 0.007) than those without TB lesions on chest CT scans, pulmonary TB may be related to the formation of EGFR mutations but not all types of EGFR mutations. On the basis of our findings, the inflammatory process of pulmonary TB may lead to cellular exon 19 deletions but not exon 21 L858R mutations.
Previous studies have suggested that the development of bronchogenic carcinoma tends to be localized in the lobe of the lung that was involved in the pulmonary TB infection. 27 Our study revealed a similar result, and we also found that patients with old pulmonary TB lesions at the same lobe or on the same side of the lung as the cancer had more tumor EGFR mutations (p ϭ 0.039), and especially exon 19 deletions (p Ͻ 0.001), than on the opposite side of the lung. According to our data, when the location of the lung cancer was closer to the old TB lesions, the proportion of tumor EGFR mutations, especially exon 19 deletions, was higher. These results suggested that the more chronic the inflammatory process the lung suffered from TB, the more EGFR mutations, especially exon 19 deletions, these patients had.
A previous study reported that survival was worse in patients with lung cancer with active pulmonary TB. 6 This study showed that patients with old TB lesions had shorter overall survival than those without. Among patients with old TB lesions, those who had tumor EGFR mutations or exon 19 deletions survived longer than those who did not (p ϭ 0.014 and 0.001, respectively), but the presence of an L858R mutation did not have an effect on overall survival (p ϭ 0.689). In the subgroup analysis of patients with stages IIIb and IV lung cancer, the results were similar. Patients with lung cancer with TB infected or damaged lung may be more vulnerable to second infection such as bacterial infection or atypical pneumonia. Once those patients suffered from second infection, repeated pneumonia and lethal nosocomial pneumonia may occur due to poor pulmonary condition. Patients are at risk for infection when receiving chemotherapy, and scheduled chemotherapy may be delayed or omitted. Disease progression is more likely to occur if the patients could not receive treatment well. So the patient with an old TB lesion had a poor prognosis. However, among patients with tumor EGFR-activating mutation, they can continue EGFR-TKI treatment even under active pulmonary infection, and this treatment is effective for their cancer control. Therefore, they have better lung cancer control.
A limitation of our study is that the patient selection was confined to those who had adenocarcinoma of the lungs, because most tumor EGFR mutations occur in adenocarcinoma of the lungs. The relationship between TB and nonadenocarcinoma lung cancer is still unknown. In addition, this was a retrospective study instead of a prospective casecontrolled study. Therefore, selection bias was inevitable, and EGFR mutation rate in our study was higher than the ordinary lung cancer population.
In conclusion, among patients with adenocarcinoma of the lung, those who had scar cancer and old TB lesions had a higher probability of having EGFR mutations, especially exon 19 deletions. The patients with scar cancer had the highest odds ratios for exon 19 deletions. These findings suggest that there exists a relationship between pulmonary TB and EGFR mutations in patients with adenocarcinoma of the lungs.
